Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?
This overview summarises recent experimental findings suggesting that an optimal motor control in Parkinson’s disease depends on concurrent activation of D-1 and D-2 receptors. The clinical observation that a combination of bromocriptine (Parlodel; Pravidel) with L-DOPA produces better symptomatic control in Parkinson patients than either agent alone is explained as the result of a synergistic interaction between D-2 receptors activated by Parlodel and D-1 receptors activated by dopamine formed from L-DOPA.
KeywordsDopamine Receptor Dopamine Agonist Endogenous Dopamine Cerebral Glucose Utilisation Sensory Motor Cortex
Unable to display preview. Download preview PDF.
- Burns RS, Phillips JM, Chiueh CC, Parisi JE (1986) The MPTP-treated monkey model of Parkinson’s disease. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ (eds) MPTP: A neurotoxin producing a Parkinsonian syndrome. Academic Press, Orlando, pp 23–42Google Scholar
- Caine DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK (1974) Treatment of Parkinsonism with bromocriptine. Lancet ii: 1355–1356Google Scholar
- Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz 0 (1978): Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 59–61Google Scholar
- Markstein R, Seiler MP, Vigouret JM, Urwyler S, Enz A, Palacios JM, Wiederhold KH, Dixon K, Hofmann A, Wuetherich H (1988) CY 208–243, a novel D-1 receptor partial agonist. European J Pharmacol (in press)Google Scholar
- Nomoto M, Jenner P, Marsden CD (1985) The dopamine D-2 agonist LY 141865, but not the D-1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP) in the common marmoset, Neurosci Lett 57: 37–41Google Scholar
- Rinne UK, Koskinen V, Loenberg P (1980) Neurotransmitter receptors in the Parkinsonian brain. In: Rinne UK, Klinger M, Stamm G (eds) Parkinson’s disease–Current progress, problems and management. Elsevier and NorthHolland Biomedical Press, pp 93–107Google Scholar
- Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist European J Pharmacol 50: 419–430Google Scholar
- Sokoloff L, Reivich M, Kennedy C, DesRosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C] deoxyglucose method for the measurement of local cerebral glucose utilisation: theory, procedure, and normal values in the conscious and anesthetised albino rat. J Neurochem. 28: 897–916PubMedCrossRefGoogle Scholar